Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The downsides of microdosing GLP-1s The main downside is that you likely wont see results quite as quickly as you would with a higher dose
The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis later reported 28.7% mean weight loss at 68 weeks with retatrutide 12 mg/week, and identified a dose-related dysesthesia (nerve-tingling) signal in 8.8% of 9 mg and 20.9% of 12 mg patients (Bays et al., 2025)
Hit up a registered dietitian or your healthcare provider to fine-tune your protein goal
FDA label now includes CV-risk reduction Expected weight loss based on studies -15% at 68 weeks based on the STEP-1 study Common side effects Nausea, vomiting, diarrhoea, constipation (moderate) Cost of medication AED 743 Scientific name Semaglutide (GLP-1 receptor agonist) FDA approval Chronic weight management in adults & adolescents 12 years with BMI 30 or BMI 27 with at least 1 comorbidity Reduction in diabetes markers SELECT trial: 20 % MACE over ~3 y
#MedicalResearch #ClinicalTrials #HealthyAging #LongevityScience #Inflammaging #Senescence #HealthcareInnovation #FutureOfMedicine #Neolaiabio To view or add a comment, sign in A new study by Anja Linde et al
Licensed compounding pharmacies receive the prescription, prepare the medication, and ship it
